Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLCBCYC · Entity 5993 | Director | January 02, 2026 | January 07, 2026 |
| INCYTE CORPINCY · Entity 3182 | Director | December 08, 2025 | December 10, 2025 |
| Maze Therapeutics, Inc.MAZE · Entity 1775 | Director | June 08, 2026 | June 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BICYCLE THERAPEUTICS PLC
Report date January 02, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 15,532 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 3,032 · Balance 15,532 F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. F2: Each RSU represents a contingent right to receive one ordinary share. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.08 · Expires 2036-01-02 | Direct | 6,065 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 6,065 · Balance 6,065 F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
F2: Each RSU represents a contingent right to receive one ordinary share.
F3: This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.
INCYTE CORP
Report date December 08, 2025 · Filed December 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 326,803 |
Reported balance
After 2025-12-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-12-08 · Tax withholding · Disposed 2,843 · Balance 326,803 F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2: This includes an aggregate of 70,643 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock.
F2: This includes an aggregate of 70,643 shares of common stock issuable pursuant to previously reported RSUs and earned performance shares that have not vested.
Maze Therapeutics, Inc.
Report date June 08, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.58 · Expires 2036-06-07 | Direct | 18,000 |
Reported balance
After 2026-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-08 · Grant · Acquired 18,000 · Balance 18,000 F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and be fully exercisable on the earlier of (i) the date of the issuer's 2027 annual stockholders meeting or (ii) June 8, 2027, subject to the reporting person's continued service to the issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2020 Filed Jul 7, 2020 23:18 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 39,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-041557 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,662 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Herve Hoppenot's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:06 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 119,501 | $0.00 Strike: $65.55 | $0.00 |
DisclosureSEC source: 0001209191-20-039435 · doc4.xml · derivative · entry 10 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 119,501 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:06 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,647 | $0.00 Strike: $64.55 | $0.00 |
DisclosureSEC source: 0001209191-20-039435 · doc4.xml · derivative · entry 9 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,647 shares Expires 2021-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Beginning January 21, 2014, options become exercisable in 25 installments, with the first 33.33% vesting after one year and the remainder vesting monthly over two years. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:06 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 119,501 | $102.91 | $12,297,847.91 |
DisclosureSEC source: 0001209191-20-039435 · doc4.xml · nonDerivative · entry 7 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,603 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $101.25 - $105.56. F4 · balance_after: This includes an aggregate of 107,977 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:06 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 119,501 | $64.55 | $7,713,789.55 |
DisclosureSEC source: 0001209191-20-039435 · doc4.xml · nonDerivative · entry 5 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 360,104 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:06 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 4,647 | $102.91 | $478,222.77 |
DisclosureSEC source: 0001209191-20-039435 · doc4.xml · nonDerivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,603 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $101.25 - $105.56. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:06 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 4,647 | $64.55 | $299,963.85 |
DisclosureSEC source: 0001209191-20-039435 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 21:29 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 40,360 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-010140 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,211 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 13, 2020. The performance shares vest 25% annually over four years from the grant date of July 2, 2019, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2020 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded, and the performance criteria was achieved at the 101.80% level. F2 · balance_after: Including the Performance Stock Units earned on February 13, 2020, this includes an aggregate of 107,977 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| January 17, 2020 Filed Jan 22, 2020 21:24 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 96,328 | $0.00 Strike: $80.50 | $0.00 |
DisclosureSEC source: 0001209191-20-004474 · doc4.xml · derivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,328 Underlying: Common Stock · 96,328 shares Expires 2030-01-16 F1 · derivative.exercise_date: Beginning January 17, 2020, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2020 and the remainder vesting monthly over three years. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 21:20 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 28,345 | $85.97 | $2,436,819.65 |
DisclosureSEC source: 0001209191-20-000931 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,851 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table 1 as common stock, which withholding was not a market transaction by the Reporting Person. F2 · balance_after: This includes an aggregate of 67,617 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 15, 2019 Filed Jul 16, 2019 21:07 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,400 | $81.39 | $195,336.00 |
DisclosureSEC source: 0001209191-19-042202 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,196 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 134,283 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 05, 2019 Filed Jul 9, 2019 20:37 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,552 | $85.28 | $132,354.56 |
DisclosureSEC source: 0001209191-19-041568 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,596 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 139,764 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 19:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 96,327 | $0.00 Strike: $85.01 | $0.00 |
DisclosureSEC source: 0001209191-19-040962 · doc4.xml · derivative · entry 5 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,327 Underlying: Common Stock · 96,327 shares Expires 2029-07-01 F5 · derivative.exercise_date: Beginning July 2, 2019, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 19:08 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,410 | $85.01 | $204,874.10 |
DisclosureSEC source: 0001209191-19-040962 · doc4.xml · nonDerivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,148 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of performance stock units previously reported in Table I as common stock. F3 · balance_after: Including the July 2, 2019 Restricted Stock Unit Grant, this includes an aggregate of 143,104 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 02, 2019 Filed Jul 3, 2019 19:08 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 39,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-040962 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,558 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Herve Hoppenot's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| February 14, 2019 Filed Feb 20, 2019 00:11 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 20,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-011330 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,503 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 14, 2019. The performance shares vest 25% annually over four years from the grant date of July 2, 2018, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Each performance share initially represented the right to receive one or more shares of common stock based on, and subject to, the achievement of revenue-based performance criteria determined by the Issuer's Compensation Committee in February 2018 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 150% of the number of performance shares awarded, and the performance criteria was achieved at the 83% level. F2 · balance_after: Includes an aggregate of 87,728 shares of common stock issuable pursuant to the performance shares reported above and previously reported restricted stock units that have not vested as of February 14, 2019. Read SEC document |
| January 07, 2019 Filed Jan 8, 2019 21:22 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 4,604 | $74.21 | $341,662.84 |
DisclosureSEC source: 0001209191-19-002773 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,532 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 87,728 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 21:22 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 88,558 | $0.00 Strike: $72.27 | $0.00 |
DisclosureSEC source: 0001209191-19-002773 · doc4.xml · derivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,558 Underlying: Common Stock · 88,558 shares Expires 2029-01-03 F4 · derivative.exercise_date: Beginning January 4, 2019, options become exercisable in 37 installments, with the first 25.00% vesting on July 2, 2019 and the remainder vesting monthly over three years. Read SEC document |
| January 02, 2019 Filed Jan 3, 2019 21:20 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 27,630 | $63.56 | $1,756,162.80 |
DisclosureSEC source: 0001209191-19-000921 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,136 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 98,170 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 16, 2018 Filed Jul 18, 2018 20:25 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,359 | $70.19 | $165,578.21 |
DisclosureSEC source: 0001209191-18-043035 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,766 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 164,837 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2018 Filed Jul 5, 2018 21:18 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,532 | $68.28 | $104,604.96 |
DisclosureSEC source: 0001209191-18-041748 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,125 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 170,238 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 21:18 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 88,557 | $0.00 Strike: $68.62 | $0.00 |
DisclosureSEC source: 0001209191-18-041748 · doc4.xml · derivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,557 Underlying: Common Stock · 88,557 shares Expires 2028-07-01 F4 · derivative.exercise_date: Beginning July 2, 2018, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| May 02, 2018 Filed May 3, 2018 21:05 UTC | INCYTE CORP INCY · Entity 3182 | PurchaseCommon Stock | 15,000 | $60.94 | $914,100.00 |
DisclosureSEC source: 0001209191-18-027697 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,690 F1 · balance_after: Includes an aggregate of 173,657 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 21:12 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 37,314 | $86.03 | $3,210,123.42 |
DisclosureSEC source: 0001209191-18-012346 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,690 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 173,657 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 24, 2018 Filed Jan 25, 2018 21:37 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 25,401 | $0.00 Strike: $95.34 | $0.00 |
DisclosureSEC source: 0001209191-18-005392 · doc4.xml · derivative · entry 2 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,401 Underlying: Common Stock · 25,401 shares Expires 2028-01-23 F2 · derivative.exercise_date: Beginning January 24, 2018, options become exercisable in full on January 24, 2022. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:37 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 47,168 | $0.00 Strike: $94.63 | $0.00 |
DisclosureSEC source: 0001209191-18-005392 · doc4.xml · derivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,168 Underlying: Common Stock · 47,168 shares Expires 2028-01-22 F1 · derivative.exercise_date: Beginning January 23, 2018, options become exercisable in 37 installments, with the first 25.00% vesting on July 5, 2018 and the remainder vesting monthly over three years. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 20:28 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 70,502 | $119.45 | $8,421,463.90 |
DisclosureSEC source: 0001209191-17-053466 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,004 F1 · price: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person. F2 · price: Reporting person undertakes to provide upon request by Securites and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $117.70 - $120.73. F4 · balance_after: Includes an aggregate of 252,916 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 20:19 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,486 | $123.15 | $306,150.90 |
DisclosureSEC source: 0001209191-17-052964 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,506 F1 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F2 · balance_after: Includes an aggregate of 252,916 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:59 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 47,168 | $0.00 Strike: $128.34 | $0.00 |
DisclosureSEC source: 0001209191-17-044422 · doc4.xml · derivative · entry 2 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,168 Underlying: Common Stock · 47,168 shares Expires 2027-07-04 F3 · derivative.exercise_date: Beginning July 5, 2017, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 20:59 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 13,679 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-044422 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,992 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Mr. Hoppenot's continued service with the Issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Includes an aggregate of 244,637 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:02 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 32,443 | $121.95 | $3,956,423.85 |
DisclosureSEC source: 0001209191-17-015342 · doc4.xml · nonDerivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,313 F4 · shares: Represents shares withheld to satisfy tax withholding obligations due at settlement of restricted stock units previously reported in Table I as common stock. F5 · balance_after: Includes an aggregate of 244,637 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 22:02 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 8,478 | $121.95 | $1,033,892.10 |
DisclosureSEC source: 0001209191-17-015342 · doc4.xml · nonDerivative · entry 2 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 390,756 F3 · shares: Represents shares withheld to satisfy tax withholding obligations with respect to vested performance shares. F2 · balance_after: Includes an aggregate of 311,304 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| February 14, 2017 Filed Feb 28, 2017 22:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 17,428 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-015342 · doc4.xml · nonDerivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 399,234 F1 · shares: Represents shares acquired upon vesting of performance shares. Each performance share represented the right to receive one or more shares of common stock based on, and subject to, the achievement of certain clinical and revenue milestones as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person was entitled to receive ranged from 0% to 125% of the number of performance shares awarded. Performance share milestones were achieved at the 100% level. F2 · balance_after: Includes an aggregate of 311,304 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | INCYTE CORP INCY · Entity 3182 | GrantIncentive Stock Option (right to buy) · Derivative | 879 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004496 · doc4.xml · derivative · entry 3 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 879 Underlying: Common Stock · 879 shares Expires 2027-01-16 F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 93,446 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004496 · doc4.xml · derivative · entry 2 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,446 Underlying: Common Stock · 93,446 shares Expires 2027-01-16 F2 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in full on January 17, 2021. Read SEC document |
| January 17, 2017 Filed Jan 19, 2017 21:33 UTC | INCYTE CORP INCY · Entity 3182 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 74,245 | $0.00 Strike: $113.64 | $0.00 |
DisclosureSEC source: 0001209191-17-004496 · doc4.xml · derivative · entry 1 Hoppenot Herve · CIK 0001596492 · Director · Chairman / CEO · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,245 Underlying: Common Stock · 74,245 shares Expires 2027-01-16 F1 · derivative.exercise_date: Beginning January 17, 2017, options become exercisable in 37 installments, with the first 25.00% vesting on July 15, 2017 and the remainder vesting monthly over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.